Lilly Open To Providing More Guidance On Duration Of Treatment With Evista
Executive Summary
The length of time that women take Lilly's Evista to decrease risk of invasive breast cancer is a decision to be made by patients and physicians, the company contended during a July 24 meeting of FDA's Oncologic Drugs Advisory Committee